1. Techne Corp. (TECH) Brenton Wanner

2. Overview Research and Diagnostic Systems, Inc. ◦ Minneapolis, Minnesota R&D Systems Europe Ltd. ◦ Abingdon, England Dev. and manu. hematology controls ◦ Check accuracy of blood analysis instruments

3. Key Stats Recent Price : $60.36 Purchase Price : $69.78 Intrinsic Value : N/A Shares : 40 Gain : ($376.80) Port Weight: 3.51% P/E: 20.5 Debt/Equity: N/A EPS Growth 3 Yr: 8.85 Net Profit Margin: 40.8 ROE: 22.91

4. Industry comparison TechneIndustry P/E: 20.5 P/B: 4.3 EPS Growth (3yr Avg): 11.0 Net Profit Margin: 40.8 ROE: 22.9 Debt/Equity: 0.0 P/E: 26.1 P/B: 2.8 EPS Growth (3yr Avg): 16.2 Net Profit Margin: 3.2 ROE: 3.7 Debt/Equity: 0.5

5. 1 yr. Graph

6. 5 yr. Graph

7. Recent News Techne Corporation Declares Dividend (10-28-10) Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2011 (10-26-10) BioInformatics, LLC New Market Reports - RNAi, Genomics and Membrane Protein Structure (10-14-10)

8. Analyst’s Recommendation Total Number of Analysts: 5 Strong Buy: 3 Buy: 1 Hold: 1 Underperform: 0 Sell: 0

9. Future Estimates Revenue expected to rise from 280.64B to 300.01B EPS expected to rise from 2.95 to 3.02 Growth next 5 years: 10.67%

10. Recommendation We should sell TECH because the company has bad financial ratios, institutional investment has decreased significantly, and is estimated to have little to no growth within the next 10 years. The company is banking off its subsidiary in China which does put them in a position for potential long term growth.